Abstract:Introduction: Malignant peripheral nerve sheath tumors (MPNST) pose a significant therapeutic challenge due to high recurrence rates after surgical resection and a largely ineffective response to traditional chemotherapy. An alternative treatment strategy is oncolytic viroimmunotherapy, which can elicit a durable and systemic antitumor immune response and is Food and Drug Administration (FDA)-approved for the treatment of melanoma. Unfortunately, only a subset of patients responds completely, underscoring the need to address barriers hindering viroimmunotherapy effectiveness. Methods: Here we investigated the therapeutic utility of targeting key components of the MPNST immunosuppressive microenvironment to enhance viroimmunotherapy's antitumor efficacy in three murine models, one of which showed more immunogenic characteristics than the others. Results: Myelomodulatory therapy with pexidartinib, a small molecule inhibitor of CSF1R tyrosine kinase, and the oncolytic herpes simplex virus T-VEC exhibited the most significant increase in median survival time in the highly immunogenic model. Additionally, targeting myeloid cells with the myelomodulatory therapy trabectedin, a small molecule activator of caspase-8 dependent apoptosis, augmented the survival benefit of T-VEC in a less immunogenic MPNST model. However, tumor regressions or shrinkages were not observed. Depletion experiments confirmed that the enhanced survival benefit relied on a T cell response. Furthermore, flow cytometry analysis following combination viroimmunotherapy revealed decreased M2 macrophages and myeloid-derived suppressor cells and increased tumor-specific gp70+ CD8 T cells within the tumor microenvironment. Discussion: In summary, our findings provide compelling evidence for the potential to leverage viroimmunotherapy with myeloid cell targeting against MPNST and warrant further investigation.

Corrigendum: Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors

Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors

Corrigendum: Establishment and immune phenotyping of patient-derived glioblastoma models in humanized mice

Corrigendum: Tumor-Associated Macrophages in Tumor Immunity

Corrigendum: Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes

Corrigendum to "Gene mutations in newly diagnosed multiple myeloma patients detected by next-generation sequencing technology" [ Cancer Pathog Ther. 2024;2:205-211]

Corrigendum to "Intrathecal non-viral interleukin-10 gene therapy ameliorates neuropathic pain as measured by both classical static allodynia and a novel supra-spinally mediated pain assay, the Two-Arm Rodent Somatosensory task" 177-185]

Corrigendum: Alternative Splicing: a New Cause and Potential Therapeutic Target in Autoimmune Disease.

Erratum: Novel permissive murine immunocompetent orthotopic colon carcinoma model for comparison of the antitumoral and safety profiles of three Adv-TKs

Corrigendum to "Equilibrative nucleoside transporter 3 supports microglial functions and protects against the progression of Huntington's disease in the mouse model" 413-429]

Corrigendum to “remodeling Tumor Immunosuppressive Microenvironment Via a Novel Bioactive Nanovaccines Potentiates the Efficacy of Cancer Immunotherapy” [bioactive Mater. 16 107–119]

Corrigendum: Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC

Correction to: The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them

Corrigendum: MicroRNA339 Targeting PDXK Improves Motor Dysfunction and Promotes Neurite Growth in the Remote Cortex Subjected to Spinal Cord Transection

Corrigendum: Light-enhanced VEGF121/rGel induce immunogenic cell death and increase the antitumor activity of αCTLA4 treatment

Corrigendum: Combination of Rapamycin and MK-2206 Induced Cell Death Via Autophagy and Necroptosis in MYCN-amplified Neuroblastoma Cell Lines.

Corrigendum: Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers

Corrigendum: Treatment of Surgical Brain Injury by Immune Tolerance Induced by Peripheral Intravenous Injection of Biotargeting Nanoparticles Loaded with Brain Antigens

[Corrigendum] Anthelmintic Pyrvinium Pamoate Blocks Wnt/β-catenin and Induces Apoptosis in Multiple Myeloma Cells

Corrigendum: Translatability of findings from cynomolgus monkey to human suggests a mechanistic role for IL-21 in promoting immunogenicity to an anti-PD-1/IL-21 mutein fusion protein

Erratum: Immunotherapy for Glioblastoma: Current Progress and Challenges